3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Endometrial Neoplasms
6
Neoplasms
5
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Neoplasms
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Carcinosarcoma
1
Neoplasms, Second Primary
1
Locally Advanced Rectal Cancer (LARC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
pembrolizumab
57
Carboplatin
34
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
Specimen Handling
15
130-nm albumin-bound paclitaxel
15
toripalimab
11
Drug Therapy
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
dostarlimab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled